Episode

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

Podcast

The Long Run with Luke Timmerman

Published

Jul 14, 2026

Duration seconds

4098

Processing state

not_requested

Canonical source

https://soundcloud.com/longrunpodcast/ep205-heather-turner-on-a

Audio

https://feeds.soundcloud.com/stream/2360461346-longrunpodcast-ep205-heather-turner-on-a.mp3

JSON

/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep205-heather-turner-on-a-schizophrenia-drug-patients-can-stick-with

Markdown

/podcast/the-long-run-with-luke-timmerman-1124799/ep205-heather-turner-on-a-schizophrenia-drug-patients-can-stick-with.md

Actions

• POST https://stenobird.com/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep205-heather-turner-on-a-schizophrenia-drug-patients-can-stick-with/transcription-requests
  Idempotently request low-priority transcript generation for this episode.
• GET https://stenobird.com/podcast/the-long-run-with-luke-timmerman-1124799/ep205-heather-turner-on-a-schizophrenia-drug-patients-can-stick-with.md
  Read the agent-friendly Markdown representation of this episode resource.

Summary

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.